Intranasal Drug Delivery Devices Market Size To Hit US$ 2.98 Billion By 2030

The global intranasal drug delivery devices market size is expected to hit around USD 2.98 billion by 2030 and progressing a CAGR of 12.8% over the forecast period 2022 to 2030.

Intranasal Drug Delivery Devices Market Size 2017 to 2030

The on intranasal drug delivery devices Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.

Download Free Sample@ https://www.precedenceresearch.com/sample/1253

Scope of the Report

Report Highlights	Details
Market Size	US$ 2.98 Billion by 2030
Growth Rate	CAGR of 12.8% from 2021 to 2030
Base Year	2020
Historic Data	2017 to 2020
Forecast Period	2021 to 2030
Segments Covered	CAGR of 12.8% during the forecast period 2021 to 2030.

A recent report provides crucial insights along with application based and forecast information in the Global Intranasal drug delivery devices Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Intranasal drug delivery devices market.

A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.

Companies and Manufacturers Covered

The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Intranasal drug delivery devices market are included as given below:

Intranasal drug delivery devices Market Key Players

Johnson & Johnson, Inc.
Aptar Pharma Group
GlaxoSmithKline Plc
Aegis Therapeutics LLC
H&T Presspart Manufacturing Ltd.
AstraZeneca Plc
Becton, Dickinson and Company
Novartis AG
Teleflex Incorporated
Vectura Group Plc.

Market Segments

By System

Metered Dose
Multi-Dose Systems
Unit-Dose Systems

By Container

Non-Pressurized Containers
Pressurized Containers

By Application

Chronic Obstructive Pulmonary Disease (COPD)
Rhinitis
Cystic Fibrosis
Nasal Congestion
Asthma
Others

By End User

Ambulatory Surgical Centers
Clinics
Hospitals
Others

By Geography

North America

U.S.
Canada

Europe

Germany
France
United Kingdom
Rest of Europe

Asia Pacific

China
Japan
India
Southeast Asia
Rest of Asia Pacific

Latin America

Brazil
Rest of Latin America

Middle East & Africa (MEA)

GCC
North Africa
South Africa
Rest of Middle East & Africa

Report Objectives

To define, describe, and forecast the global intranasal drug delivery devices market based on product, and region
To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the intranasal drug delivery devices market

Table of Content

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Intranasal Drug Delivery Devices Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Intranasal Drug Delivery Devices Market

5.1. Covid-19: Intranasal Drug Delivery Devices Industry Impact
5.2. Intranasal Drug Delivery Devices Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Intranasal Drug Delivery Devices Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Intranasal Drug Delivery Devices Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Intranasal Drug Delivery Devices Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. High prevalence of cardiovascular diseases
6.1.1.2. Patent expiration of popular drugs, increased cases of cancer and diabetes
6.1.2. Market Restraints
6.1.2.1. Complications Associated with the Overuse
6.1.3. Market Opportunities
6.1.3.1. Growing adoption of self-administration practices
6.1.3.2. Technological advancements

Chapter 7. Global Intranasal Drug Delivery Devices Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Intranasal Drug Delivery Devices Market Revenue by Market Players (2016 -2019)
7.1.1.2. Intranasal Drug Delivery Devices Market Revenue Market Share by Market Players (2016 -2019)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, System Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users

Chapter 8. Global Intranasal Drug Delivery Devices Market, By System

8.1. Intranasal Drug Delivery Devices Market, by System, 2016-2027
8.1.1. Metered Dose
8.1.1.1. Market Revenue and Forecast (2016-2027)
8.1.2. Multi-Dose Systems
8.1.2.1. Market Revenue and Forecast (2016-2027)
8.1.3. Unit-Dose Systems
8.1.3.1. Market Revenue and Forecast (2016-2027)

Chapter 9. Global Intranasal Drug Delivery Devices Market, By Container

9.1. Intranasal Drug Delivery Devices Market, by Container, 2016-2027
9.1.1. Non-Pressurized Containers
9.1.1.1. Market Revenue and Forecast (2016-2027)
9.1.2. Pressurized Containers
9.1.2.1. Market Revenue and Forecast (2016-2027)

Chapter 10. Global Intranasal Drug Delivery Devices Market, By Application

10.1. Intranasal Drug Delivery Devices Market, by Application, 2016-2027
10.1.1. Chronic Obstructive Pulmonary Disease (COPD)
10.1.1.1. Market Revenue and Forecast (2016-2027)
10.1.2. Rhinitis
10.1.2.1. Market Revenue and Forecast (2016-2027)
10.1.3. Cystic Fibrosis
10.1.3.1. Market Revenue and Forecast (2016-2027)
10.1.4. Nasal Congestion
10.1.4.1. Market Revenue and Forecast (2016-2027)
10.1.5. Asthma
10.1.5.1. Market Revenue and Forecast (2016-2027)
10.1.6. Others
10.1.6.1. Market Revenue and Forecast (2016-2027)

Chapter 11. Global Intranasal Drug Delivery Devices Market, By End User

11.1. Intranasal Drug Delivery Devices Market, by End User, 2016-2027
11.1.1. Ambulatory Surgical Centers
11.1.1.1. Market Revenue and Forecast (2016-2027)
11.1.2. Clinics
11.1.2.1. Market Revenue and Forecast (2016-2027)
11.1.3. Hospitals
11.1.3.1. Market Revenue and Forecast (2016-2027)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2016-2027)

Chapter 12. Global Intranasal Drug Delivery DevicesMarket, Regional Estimates and Trend Forecast

12.1. North America
12.1.1. Market Revenue Forecast by System(2016-2027)
12.1.2. Market Revenue Forecast by Container(2016-2027)
12.1.3. Market Revenue Forecast by Application(2016-2027)
12.1.4. Market Revenue Forecast by End User (2016-2027)
12.1.5. U.S
12.1.5.1. Market Revenue Forecast (2016-2027)
12.1.6. Canada
12.1.6.1. Market Revenue Forecast (2016-2027)
12.2. Europe
12.2.1. Market Revenue Forecast by System (2016-2027)
12.2.2. Market Revenue Forecast by Container (2016-2027)
12.2.3. Market Revenue Forecast by Application (2016-2027)
12.2.4. Market Revenue Forecast by End User (2016-2027)
12.2.5. UK
12.2.5.1. Market Revenue Forecast (2016-2027)
12.2.6. Germany
12.2.6.1. Market Revenue Forecast (2016-2027)
12.2.7. France
12.2.7.1. Market Revenue Forecast (2016-2027)
12.2.8. Rest of EU
12.2.8.1. Market Revenue Forecast (2016-2027)
12.3. Asia Pacific (APAC)
12.3.1. Market Revenue Forecast by System (2016-2027)
12.3.2. Market Revenue Forecast by Container (2016-2027)
12.3.3. Market Revenue Forecast by Application (2016-2027)
12.3.4. Market Revenue Forecast by End User (2016-2027)
12.3.5. China
12.3.5.1. Market Revenue Forecast (2016-2027)
12.3.6. India
12.3.6.1. Market Revenue Forecast (2016-2027)
12.3.7. Japan
12.3.7.1. Market Revenue Forecast (2016-2027)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue Forecast (2016-2027)
12.4. LATAM
12.4.1. Market Revenue Forecast by System (2016-2027)
12.4.2. Market Revenue Forecast by Container (2016-2027)
12.4.3. Market Revenue Forecast by Application (2016-2027)
12.4.4. Market Revenue Forecast by End User (2016-2027)
12.4.5. Brazil
12.4.5.1. Market Revenue Forecast (2016-2027)
12.4.6. Rest of LATAM
12.4.6.1. Market Revenue Forecast (2016-2027)
12.5. Middle East and Africa (MEA)
12.5.1. Market Revenue Forecast by System (2016-2027)
12.5.2. Market Revenue Forecast by Container (2016-2027)
12.5.3. Market Revenue Forecast by Application (2016-2027)
12.5.4. Market Revenue Forecast by End User (2016-2027)
12.5.5. GCC
12.5.5.1. Market Revenue Forecast (2016-2027)
12.5.6. North Africa
12.5.6.1. Market Revenue Forecast (2016-2027)
12.5.7. South Africa
12.5.7.1. Market Revenue Forecast (2016-2027)
12.5.8. Rest of MEA
12.5.8.1. Market Revenue Forecast (2016-2027)

Chapter 13. Company Profiles

13.1. Johnson & Johnson, Inc.
13.1.1. Company Overview, Business Information, Regional Presence
13.1.2. Product Portfolio Analysis
13.1.2.1. Product Details, Specification, Application
13.1.3. Revenue, Price, and Gross Margin (2015-2020)
13.1.4. Recent Developments and Strategies
13.2. Aptar Pharma Group
13.2.1. Company Overview, Business Information, Regional Presence
13.2.2. Product Portfolio Analysis
13.2.2.1. Product Details, Specification, Application
13.2.3. Revenue, Price, and Gross Margin (2015-2020)
13.2.4. Recent Developments and Strategies
13.3. GlaxoSmithKline Plc
13.3.1. Company Overview, Business Information, Regional Presence
13.3.2. Product Portfolio Analysis
13.3.2.1. Product Details, Specification, Application
13.3.3. Revenue, Price, and Gross Margin (2015-2020)
13.3.4. Recent Developments and Strategies
13.4. Aegis Therapeutics LLC
13.4.1. Company Overview, Business Information, Regional Presence
13.4.2. Product Portfolio Analysis
13.4.2.1. Product Details, Specification, Application
13.4.3. Revenue, Price, and Gross Margin (2015-2020)
13.4.4. Recent Developments and Strategies
13.5. H&T Presspart Manufacturing Ltd.
13.5.1. Company Overview, Business Information, Regional Presence
13.5.2. Product Portfolio Analysis
13.5.2.1. Product Details, Specification, Application
13.5.3. Revenue, Price, and Gross Margin (2015-2020)
13.5.4. Recent Developments and Strategies
13.6. AstraZeneca Plc
13.6.1. Company Overview, Business Information, Regional Presence
13.6.2. Product Portfolio Analysis
13.6.2.1. Product Details, Specification, Application
13.6.3. Revenue, Price, and Gross Margin (2015-2020)
13.6.4. Recent Developments and Strategies
13.7. Becton, Dickinson and Company
13.7.1. Company Overview, Business Information, Regional Presence
13.7.2. Product Portfolio Analysis
13.7.2.1. Product Details, Specification, Application
13.7.3. Revenue, Price, and Gross Margin (2015-2020)
13.7.4. Recent Developments and Strategies
13.8. Novartis AG
13.8.1. Company Overview, Business Information, Regional Presence
13.8.2. Product Portfolio Analysis
13.8.2.1. Product Details, Specification, Application
13.8.3. Revenue, Price, and Gross Margin (2015-2020)
13.8.4. Recent Developments and Strategies
13.9. Teleflex Incorporated
13.9.1. Company Overview, Business Information, Regional Presence
13.9.2. Product Portfolio Analysis
13.9.2.1. Product Details, Specification, Application
13.9.3. Revenue, Price, and Gross Margin (2015-2020)
13.9.4. Recent Developments and Strategies
13.10. Vectura Group Plc.
13.10.1. Company Overview, Business Information, Regional Presence
13.10.2. Product Portfolio Analysis
13.10.2.1. Product Details, Specification, Application
13.10.3. Revenue, Price, and Gross Margin (2015-2020)
13.10.4. Recent Developments and Strategies